Holecistokininski receptor B (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Holecistokininski receptor B" in Serbian language version.

refsWebsite

Global rank Serbian rank

13nih.gov

4^th place

8^th place

11doi.org

2^nd place

4^th place

2archive.org

6^th place

5^th place

1lww.com

2,769^th place

1,062^nd place

archive.org

Aloj L, Caracò C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, De Luca S, Arra C, Pedone C, Morelli G, Salvatore M (2004). „In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging”. J. Nucl. Med. 45 (3): 485—94. PMID 15001692.
Higgins GA, Sills TL, Tomkins DM, Sellers EM, Vaccarino FJ (1994). „Evidence for the contribution of CCKB receptor mechanisms to individual differences in amphetamine-induced locomotion”. Pharmacol. Biochem. Behav. 48 (4): 1019—24. PMID 7972279. doi:10.1016/0091-3057(94)90214-3.

doi.org

Noble F, Roques BP (1999). „CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology”. Prog. Neurobiol. 58 (4): 349—79. PMID 10368033. doi:10.1016/S0301-0082(98)00090-2.
Pisegna JR, de Weerth A, Huppi K, Wank SA (1992). „Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization”. Biochem. Biophys. Res. Commun. 189 (1): 296—303. PMID 1280419. doi:10.1016/0006-291X(92)91557-7.
Harikumar KG, Clain J, Pinon DI, Dong M, Miller LJ (2005). „Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy”. J. Biol. Chem. 280 (2): 1044—50. PMID 15520004. doi:10.1074/jbc.M409480200.
Galés C, Poirot M, Taillefer J, Maigret B, Martinez J, Moroder L, Escrieut C, Pradayrol L, Fourmy D, Silvente-Poirot S (2003). „Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis, and structure/affinity studies”. Mol. Pharmacol. 63 (5): 973—82. PMID 12695525. doi:10.1124/mol.63.5.973.
Altar CA, Boyar WC (1989). „Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin”. Brain Res. 483 (2): 321—6. PMID 2706523. doi:10.1016/0006-8993(89)90176-5.
Loonam TM, Noailles PA, Yu J, Zhu JP, Angulo JA (2003). „Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum”. Life Sci. 73 (6): 727—39. PMID 12801594. doi:10.1016/S0024-3205(03)00393-X.
Lanza M, Makovec F (2000). „Cholecystokinin (CCK) increases GABA release in the rat anterior nucleus accumbens via CCK(B) receptors located on glutamatergic interneurons”. Naunyn Schmiedebergs Arch. Pharmacol. 361 (1): 33—8. PMID 10651144. doi:10.1007/s002109900161.
Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD (1990). „The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat”. Eur. J. Pharmacol. 176 (1): 35—44. PMID 2311658. doi:10.1016/0014-2999(90)90129-T.
Higgins GA, Sills TL, Tomkins DM, Sellers EM, Vaccarino FJ (1994). „Evidence for the contribution of CCKB receptor mechanisms to individual differences in amphetamine-induced locomotion”. Pharmacol. Biochem. Behav. 48 (4): 1019—24. PMID 7972279. doi:10.1016/0091-3057(94)90214-3.
Lu L, Huang M, Ma L, Li J (2001). „Different role of cholecystokinin (CCK)-A and CCK-B receptors in relapse to morphine dependence in rats”. Behav. Brain Res. 120 (1): 105—10. PMID 11173090. doi:10.1016/S0166-4328(00)00361-2.
Boyce S, Rupniak NM, Tye S, Steventon MJ, Iversen SD (1990). „Modulatory role for CCK-B antagonists in Parkinson's disease”. Clin Neuropharmacol. 13 (4): 339—47. PMID 1976438. doi:10.1097/00002826-199008000-00009.

lww.com

journals.lww.com

Boyce S, Rupniak NM, Tye S, Steventon MJ, Iversen SD (1990). „Modulatory role for CCK-B antagonists in Parkinson's disease”. Clin Neuropharmacol. 13 (4): 339—47. PMID 1976438. doi:10.1097/00002826-199008000-00009.

nih.gov

ncbi.nlm.nih.gov

Noble F, Roques BP (1999). „CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology”. Prog. Neurobiol. 58 (4): 349—79. PMID 10368033. doi:10.1016/S0301-0082(98)00090-2.
Pisegna JR, de Weerth A, Huppi K, Wank SA (1992). „Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization”. Biochem. Biophys. Res. Commun. 189 (1): 296—303. PMID 1280419. doi:10.1016/0006-291X(92)91557-7.
Harikumar KG, Clain J, Pinon DI, Dong M, Miller LJ (2005). „Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy”. J. Biol. Chem. 280 (2): 1044—50. PMID 15520004. doi:10.1074/jbc.M409480200.
Aloj L, Caracò C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, De Luca S, Arra C, Pedone C, Morelli G, Salvatore M (2004). „In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging”. J. Nucl. Med. 45 (3): 485—94. PMID 15001692.
Galés C, Poirot M, Taillefer J, Maigret B, Martinez J, Moroder L, Escrieut C, Pradayrol L, Fourmy D, Silvente-Poirot S (2003). „Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis, and structure/affinity studies”. Mol. Pharmacol. 63 (5): 973—82. PMID 12695525. doi:10.1124/mol.63.5.973.
„Entrez Gene: CCKBR cholecystokinin B receptor”.
Altar CA, Boyar WC (1989). „Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin”. Brain Res. 483 (2): 321—6. PMID 2706523. doi:10.1016/0006-8993(89)90176-5.
Loonam TM, Noailles PA, Yu J, Zhu JP, Angulo JA (2003). „Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum”. Life Sci. 73 (6): 727—39. PMID 12801594. doi:10.1016/S0024-3205(03)00393-X.
Lanza M, Makovec F (2000). „Cholecystokinin (CCK) increases GABA release in the rat anterior nucleus accumbens via CCK(B) receptors located on glutamatergic interneurons”. Naunyn Schmiedebergs Arch. Pharmacol. 361 (1): 33—8. PMID 10651144. doi:10.1007/s002109900161.
Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD (1990). „The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat”. Eur. J. Pharmacol. 176 (1): 35—44. PMID 2311658. doi:10.1016/0014-2999(90)90129-T.
Higgins GA, Sills TL, Tomkins DM, Sellers EM, Vaccarino FJ (1994). „Evidence for the contribution of CCKB receptor mechanisms to individual differences in amphetamine-induced locomotion”. Pharmacol. Biochem. Behav. 48 (4): 1019—24. PMID 7972279. doi:10.1016/0091-3057(94)90214-3.
Lu L, Huang M, Ma L, Li J (2001). „Different role of cholecystokinin (CCK)-A and CCK-B receptors in relapse to morphine dependence in rats”. Behav. Brain Res. 120 (1): 105—10. PMID 11173090. doi:10.1016/S0166-4328(00)00361-2.
Boyce S, Rupniak NM, Tye S, Steventon MJ, Iversen SD (1990). „Modulatory role for CCK-B antagonists in Parkinson's disease”. Clin Neuropharmacol. 13 (4): 339—47. PMID 1976438. doi:10.1097/00002826-199008000-00009.